Chemical structure of fluvastatin
Find information on thousands of medical conditions and prescription drugs.

Fluvastatin

Fluvastatin (Lescol®, Canef®) is a member of the drug class of statins, used to treat hypercholesterolemia and to prevent cardiovascular disease.


Home
Diseases
Medicines
A
B
C
D
E
F
Captagon
Famohexal
Famotidine
Faslodex
Faslodex
Fasoracetam
Felbamate
Felbatol
Felodipine
Felypressin
Femara
Femara
Fempatch
Femring
Fenfluramine
Fenofibrate
Fentanyl
Fexofenadine
Filgrastim
Filipin
Finasteride
Fioricet
Fiorinal
Flagyl
Flarex
Flavoxate
Flecainide
Flexeril
Flomax
Flonase
Flovent
Floxuridine
Fluacizine
Flucloxacillin
Fluconazole
Flucytosine
Fludarabine
Fludrocortisone
Flumazenil
Flunisolide
Flunitrazepam
Fluocinonide
Fluohexal
Fluorometholone
Fluorouracil
Fluoxetine
Fluphenazine
Flurazepam
Flutamide
Fluticasone
Fluvastatin
Fluvoxamine
FML
Focalin
Folic acid
Follutein
Fomepizole
Formoterol
Fortamet
Fortovase
Fosamax
Fosinopril
Fosinoprilat
Fosmidomycin
Fosphenytoin
Frova
Frovatriptan
Frusehexal
Fulvestrant
Fumagillin
Furazolidone
Furosemide
Furoxone
Fusafungine
Fusidic acid
Fuzeon
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


New use and labeling approval for Fluvastatin
From Nurse Practitioner, 5/1/99

Fluvastatin sodium (Lescol) is now approved for an additional indication: reducing triglycerides and apolipoprotein B (Apo B) in patients with mixed dyslipidemia. Fluvastatin is a product of Novartis.

The Food and Drug Administration (FDA) based the approval on data from trials involving more than 1,600 patients with hypercholesterolemia and mixed dyslipidemia. Fluvastatin (40 mg and 80 mg) reduced triglycerides by 19.6% and 23.3%, respectively, and reduced Apo B by 18.3% and 28.1%, respectively, in patients with baseline triglycerides equal to or above 200 mg/dl.

The FDA also changed fluvastatin's labeling to reflect the need for fewer liver function tests (LFTs) for patients taking the drug. The new requirement is for LFT monitoring before starting therapy and at 12 weeks following treatment start or dose elevation. If results are normal, no further tests are required. Close monitoring of any LFT abnormality is still recommended.

Copyright Springhouse Corporation May 1999
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Fluvastatin
Home Contact Resources Exchange Links ebay